Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | DRD1 | P21728 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | CCR2 | P41597 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | MIF | P14174 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207554 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL29374052 | 0.82 | ALDH1A1 (0.62) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL3639049 | 0.76 | CYP3A4 (0.52) | ALDH1A1CYP3A4HPGDTDP1GABRA1 | |
| SCHEMBL4466979 | 0.75 | ALDH1A1 (0.56) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL24660121 | 0.71 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL484005 | 0.71 | CYP3A4 (0.52) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL348805 | 0.71 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL458499 | 0.71 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL1325334 | 0.71 | ALDH1A1 (0.52) | ALDH1A1CYP3A4HPGDABCB11NR3C1 | |
| SCHEMBL8391915 | 0.71 | L3MBTL1 (0.54) | ALDH1A1CYP3A4HPGDABCB11NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877163-B2 | Cycloalkyl triamine pentacarboxylate as ligands for paramagnetic metal complexes | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-11-04 | — | — | US | claimed |
| US-20070207087-A1 | Cycloalkyl triamine pentacarboxylate as ligands for paramagnetic metal complexes | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2007-09-06 | — | — | US | claimed |
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | SCHERING AG (DE) | 2004-12-23 | — | — | US | claimed |
| EP-1465938-A1 | DENDRITIC POLY (AMINO ACID) CARRIERS AND METHODS OF USE | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2004-10-13 | — | — | EP | claimed |
| EP-1397339-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | Schering Aktiengesellschaft (DE) | 2004-03-17 | — | — | EP | claimed |
| US-20030232968-A1 | Dendritic poly (amino acid) carriers and methods of use | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-18 | — | — | US | claimed |
| WO-2003055935-A1 | DENDRITIC POLY (AMINO ACID) CARRIERS AND METHODS OF USE | BOARD OF REGENTS - THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-07-10 | — | — | WO | claimed |
| EP-1277728-A1 | Novel TTDA derivatives and their use as gadolinium chelators for MRI imaging | University of Lausanne (CH) | 2003-01-22 | — | — | EP | claimed |
| WO-2003000647-A1 | (ETHYLENE)-(PROPYLENE)-TRIAMINEPENTAACETIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL AGENTS | SCHERING AG (DE) | 2003-01-03 | — | — | WO | claimed |
| US-20240182501-A1 | COMPLEX COMPRISING A PSMA-TARGETING COMPOUND LINKED TO A LEAD OR THORIUM RADIONUCLIDE | Sciencons AS (NO) | 2024-06-06 | — | — | US | disclosed |
| US-20240123031-A1 | METHODS OF TREATING LIVER DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2024-04-18 | — | — | US | disclosed |
| US-11951168-B2 | Composition containing buffer | PERSEUS PROTEOMICS INC. (JP) | 2024-04-09 | — | — | US | disclosed |
| WO-2024063648-A1 | Platform and scaffold for FAP targeting agents | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM (NL) | 2024-03-28 | — | — | WO | disclosed |
| EP-4342890-A1 | PLATFORM AND SCAFFOLD FOR FAP TARGETING AGENTS | Erasmus University Rotterdam Medical Center (NL) | 2024-03-27 | — | — | EP | disclosed |
| US-5275801-A | X-ray and magnetic resonance imaging of tumors | SCHERING AKTIENGESELLSCHAFT (DE) | 1994-01-04 | — | — | US | disclosed |
| WO-1993002652-A2 | MODIFIED HAPTENS USEFUL AS IMAGING AND THERAPEUTIC AGENTS | HYBRITECH INCORPORATED (US) | 1993-02-18 | — | — | WO | disclosed |
| EP-0327365-A2 | Improvements in or relating to modified haptens useful as imaging and therapeutic agents | HYBRITECH INCORPORATED (US) | 1989-08-09 | — | — | EP | disclosed |
| US-4709016-A | Molecular analytical release tags and their use in chemical analysis | NORTHEASTERN UNIVERSITY (US) | 1987-11-24 | — | — | US | disclosed |
| US-4650750-A | Method of chemical analysis employing molecular release tag compounds | GIESE ROGER W (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0085554-A1 | Molecular analytical release tags and their use in chemical analysis | NORTHEASTERN UNIVERSITY (US) | 1983-08-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182501-A1 | COMPLEX COMPRISING A PSMA-TARGETING COMPOUND LINKED TO A LEAD OR THORIUM RADIONUCLIDE | PSMA7, PSMA2, FOLH1 | ALDH1A1 4447/4885CYP3A4 4046/4885HPGD 3802/4885 |
| US-20040258620-A1 | (Ethylene)-( propylene)-triaminepentaacetic acid derivatives, process for their production, and their use for the production of pharmaceutical agents | EEA1, PCTP, TTPA | ALDH1A1 1591/4885CYP3A4 2017/4885HPGD 943/4885 |
| US-20240123031-A1 | METHODS OF TREATING LIVER DISEASES | HDGF, FGF1, HGF | ALDH1A1 567/4885CYP3A4 4355/4885HPGD 572/4885 |
| US-11951168-B2 | Composition containing buffer | SDHB, SDHA, FH | ALDH1A1 1337/4885CYP3A4 3745/4885HPGD 613/4885 |
| US-20070207087-A1 | Cycloalkyl triamine pentacarboxylate as ligands for paramagnetic metal complexes | SLC39A14, PLPBP, TSPO | ALDH1A1 4611/4885CYP3A4 4582/4885HPGD 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.